p16+ Tumor Stratification Assay for Oropharyngeal Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic and treatment strategies for oropharyngeal squamous cell carcinoma (OPSCC), particularly for p16+ tumors, lack specificity and fail to identify non-responsive tumors, leading to inadequate treatment approaches and potential recurrence.
Innovation Solution
A method involving the measurement and detection of specific gene expression profiles, including genes such as C3, CD274, CMA1, and others, to identify non-responsive p16+ cancer tumors, and determining HPV integration status to tailor treatment approaches.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current standard diagnostic and treatment strategies are used for p16+ tumors, then treatment can be applied uniformly to all patients, but the inability to identify non-responsive tumors leads to inadequate treatment and potential recurrence
Solution Approach 1:
The patent segments p16+ tumors into distinct molecular subtypes based on gene expression profiles (e.g., immune-desert, immune-excluded, immune-inflamed subtypes). This segmentation allows identification of non-responsive tumors that would otherwise be treated uniformly, thereby improving treatment reliability by matching therapy to specific tumor characteristics.
Solution Approach 2:
The patent utilizes changes in gene expression parameters (e.g., expression levels of C3, CD274, CMA1, and other genes) to differentiate tumor responsiveness. By measuring and comparing these molecular parameters against established profiles, the method identifies non-responsive tumors, enabling precise treatment stratification and improving overall treatment effectiveness.
2Measurement precision
If gene expression measurement of multiple genes is performed to identify non-responsive tumors, then tumor stratification precision is improved, but assay complexity increases
Solution Approach 1:
The patent employs a multi-gene expression assay platform that simultaneously measures multiple genes (C3, CD274, CMA1, and others) in a single test. This universal approach provides comprehensive tumor stratification information across multiple molecular dimensions, achieving high measurement precision while consolidating multiple measurements into one integrated assay system.
Solution Approach 2:
The patent combines measurement of multiple gene expression parameters into a unified assay methodology. By merging the detection of various genes (including immune-related genes like CD274 and complement genes like C3) into a single comprehensive test, the approach achieves accurate tumor stratification without requiring separate individual tests for each gene, thereby managing assay complexity.
3Reliability
If personalized treatment strategies are implemented based on molecular profiling, then treatment outcomes are improved, but diagnostic and treatment management complexity increases
Solution Approach 1:
The patent performs preliminary molecular profiling and tumor stratification before treatment decision-making. By预先 identifying tumor subtype and responsiveness markers through gene expression measurement, the system enables informed treatment selection in advance, improving outcomes while streamlining subsequent treatment management by avoiding the need for complex real-time adjustments.
Solution Approach 2:
The patent applies localized molecular profiling focused on specific gene sets (e.g., immune-related genes, complement genes) relevant to tumor responsiveness. This targeted approach provides locally optimized diagnostic information for treatment decision-making, achieving improved treatment outcomes through precise molecular characterization without requiring comprehensive analysis of all possible genetic factors, thus managing complexity.
Data Source
AI summary
Described herein are assays and methods to detect and/or treat a non-responsive or treatment resistant p16 positive tumor in a subject in need thereof. The disclosed method can also involve determining if the subject is HPV positive or negative, whether the HPV is integrated or episomal, and selecting a suitable treatment based on these determinations. Also disclosed herein is a method of treating an oropharyngeal squamous cell carcinoma in a subject using the arrays and methods disclosed herein.